Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cancer Survival Analysis01:21

Cancer Survival Analysis

807
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
807
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

6.3K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
6.3K
Kaplan-Meier Approach01:24

Kaplan-Meier Approach

674
The Kaplan-Meier estimator is a non-parametric method used to estimate the survival function from time-to-event data. In medical research, it is frequently employed to measure the proportion of patients surviving for a certain period after treatment. This estimator is fundamental in analyzing time-to-event data, making it indispensable in clinical trials, epidemiological studies, and reliability engineering. By estimating survival probabilities, researchers can evaluate treatment effectiveness,...
674
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

3.8K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.8K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

9.0K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.0K
Cancer Therapies02:49

Cancer Therapies

10.5K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
10.5K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Non-Metastatic Squamous Cell Carcinoma of the Oropharynx: Primary Surgery or (Chemo)radiotherapy?

Head & neck·2026
Same author

Reply to Borewad et al. Comment on "Rao et al. The Oncological Outcome of Postoperative Radiotherapy in Patients with Node-Negative Early-Stage (T1/T2/N0) Oral Squamous Cell Carcinoma and Perineural Invasion: A Meta-Analysis. <i>Cancers</i> 2025, <i>17</i>, 862".

Cancers·2026
Same author

Selection Criteria for De-Escalated Chemoradiotherapy for HPV-Related Oropharyngeal Cancer Based on Prognostic Biomarkers or Early Tumor Response to Therapy: A Narrative Review.

Diagnostics (Basel, Switzerland)·2026
Same author

Quantitative Imaging Advances in HPV-Positive Oropharyngeal Carcinoma.

Cancers·2026
Same author

Neutrophil to Lymphocyte and Lymphocyte to Monocyte Ratios Predict Improved Survival and Response to Induction Chemotherapy in Locally Advanced Squamous Cell Carcinoma of the Larynx.

Head & neck·2025
Same author

Bayesian Monte Carlo Simulation Based on Systematic Review for Personalized Risk Stratification of Contralateral Lymph Node Metastasis in Oral Squamous Cell Carcinoma.

Diagnostics (Basel, Switzerland)·2025

Related Experiment Video

Updated: Mar 8, 2026

Learning Modern Laryngeal Surgery in a Dissection Laboratory
07:30

Learning Modern Laryngeal Surgery in a Dissection Laboratory

Published on: March 18, 2020

8.8K

Survival Rates Using Individualized Bioselection Treatment Methods in Patients With Advanced Laryngeal Cancer.

Gregory T Wolf1, Emily Bellile2, Avraham Eisbruch3

  • 1Department of Otolaryngology-Head and Neck Surgery, University of Michigan Health System, Ann Arbor.

JAMA Otolaryngology-- Head & Neck Surgery
|February 3, 2017
PubMed
Summary
This summary is machine-generated.

A single cycle of neoadjuvant chemotherapy improved survival for advanced laryngeal cancer patients. This bioselective approach, along with primary surgery, showed better outcomes than concurrent chemoradiotherapy, highlighting the need for individualized treatment strategies.

More Related Videos

Treatment of Liver Metastases Using an Internal Target Volume Method for Stereotactic Body Radiotherapy
08:54

Treatment of Liver Metastases Using an Internal Target Volume Method for Stereotactic Body Radiotherapy

Published on: May 8, 2018

15.1K
Therapy Testing in a Spheroid-based 3D Cell Culture Model for Head and Neck Squamous Cell Carcinoma
06:11

Therapy Testing in a Spheroid-based 3D Cell Culture Model for Head and Neck Squamous Cell Carcinoma

Published on: April 20, 2018

10.4K

Related Experiment Videos

Last Updated: Mar 8, 2026

Learning Modern Laryngeal Surgery in a Dissection Laboratory
07:30

Learning Modern Laryngeal Surgery in a Dissection Laboratory

Published on: March 18, 2020

8.8K
Treatment of Liver Metastases Using an Internal Target Volume Method for Stereotactic Body Radiotherapy
08:54

Treatment of Liver Metastases Using an Internal Target Volume Method for Stereotactic Body Radiotherapy

Published on: May 8, 2018

15.1K
Therapy Testing in a Spheroid-based 3D Cell Culture Model for Head and Neck Squamous Cell Carcinoma
06:11

Therapy Testing in a Spheroid-based 3D Cell Culture Model for Head and Neck Squamous Cell Carcinoma

Published on: April 20, 2018

10.4K

Area of Science:

  • Oncology
  • Head and Neck Surgery

Background:

  • Chemoradiotherapy is a common treatment for advanced laryngeal cancer, but survival rates have not improved.
  • The initial goal of matching neoadjuvant chemotherapy response to guide treatment has not been consistently applied.

Purpose of the Study:

  • To evaluate if a single cycle of neoadjuvant chemotherapy can improve survival in advanced laryngeal cancer patients.
  • To determine if this approach can effectively select patients for subsequent laryngectomy or concurrent chemoradiotherapy.

Main Methods:

  • A retrospective analysis of 247 laryngeal cancer patients treated between 2002 and 2012.
  • Patients with limited disease underwent endoscopic resection, radiotherapy, or chemoradiotherapy.
  • Advanced disease patients received neoadjuvant chemotherapy, concurrent chemoradiotherapy, or primary surgery, with survival analyzed.

Main Results:

  • Five-year overall survival (OS) and disease-specific survival (DSS) for the entire cohort were 75% and 83%, respectively.
  • For advanced disease, DSS was 91% for surgery, 79% for neoadjuvant chemotherapy, and 66% for primary chemoradiotherapy.
  • Propensity-adjusted analysis showed significantly improved DSS in the neoadjuvant chemotherapy group compared to the chemoradiotherapy group (HR, 0.48).

Conclusions:

  • A bioselective treatment strategy using neoadjuvant chemotherapy resulted in superior survival rates for advanced laryngeal cancer.
  • Both neoadjuvant chemotherapy and primary surgery demonstrated better survival than concurrent chemoradiotherapy.
  • The optimal individualized treatment for advanced laryngeal cancer remains to be defined.